Asparaginase Escherichia coli
- Generic Name
- Asparaginase Escherichia coli
- Brand Names
- Rylaze, Spectrila
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 9015-68-3
- Unique Ingredient Identifier
- G4FQ3CKY5R
- Background
Asparaginase derived from Escherichia coli (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from E. coli has clinically shown to exh...
- Indication
Indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL)
- Associated Therapies
- -
Comparison of Different Combination Chemotherapy Regimens in Treating Infants With Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-17
- Lead Sponsor
- Dutch Childhood Oncology Group
- Target Recruit Count
- 350
- Registration Number
- NCT00015873
- Locations
- 🇮🇹
Ospedale San Gerardo, Monza, Italy
🇳🇱Erasmus MC - Sophia Children's Hospital, Rotterdam, Netherlands
🇬🇧Royal Liverpool Children's Hospital, Alder Hey, Liverpool, England, United Kingdom
Combination Chemotherapy in Treating Children With Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 179
- Registration Number
- NCT00003650
- Locations
- 🇫🇷
Centre Leon Berard, Lyon, France
Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2011-01-21
- Target Recruit Count
- 1500
- Registration Number
- NCT00003728
- Locations
- 🇵🇹
Hospital Escolar San Joao, Porto, Portugal
🇵🇹Instituto Portugues de Oncologia Centro do Porto, SA, Porto, Portugal
🇫🇷CHR de Besancon - Hopital Saint-Jacques, Besancon, France
Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2019-08-06
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 393
- Registration Number
- NCT00004228
- Locations
- 🇺🇸
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, United States
🇺🇸Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, Florida, United States
🇺🇸MBCCOP - Medical College of Georgia Cancer Center, Augusta, Georgia, United States
Stem Cell Transplantation Compared With Standard Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia in First Remission
- Conditions
- Interventions
- Biological: sargramostimDrug: cyclophosphamideDrug: asparaginaseDrug: cytarabineDrug: dexamethasoneDrug: daunorubicin hydrochlorideDrug: etoposideDrug: imatinib mesylateDrug: leucovorin calciumDrug: mercaptopurineDrug: methotrexateDrug: prednisoneDrug: thioguanineDrug: vincristine sulfateProcedure: allogeneic bone marrow transplantationRadiation: radiation therapyProcedure: autologous bone marrow transplantationProcedure: peripheral blood stem cell transplantation
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 1929
- Registration Number
- NCT00002514
- Locations
- 🇺🇸
Drexel University College of Medicine - Center City Hahnemann Campus, Philadelphia, Pennsylvania, United States
🇺🇸MetroHealth Cancer Care Center at MetroHealth Medical Center, Cleveland, Ohio, United States
🇺🇸Swedish Medical Center, Englewood, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.